In January, Personalis made the decision to slash its workforce by approximately 30% and took other measures, including closing their facility in China, that should chop payroll and other expenses by an estimated $20 million annually.

Source: https://seekingalpha.com/article/4594514-personalis-revisiting-the-investment-thesis?source=feed_all_articles

Over the years, Personalis has worked with several companies by providing genomic test information about the patient's cancer so that a personalized vaccine could be developed specifically for each individual patient.

Source: https://seekingalpha.com/article/4599697-personalis-inc-psnl-q1-2023-earnings-call-transcript?source=feed_all_articles

Prelude Capital Management LLC purchased a new stake in Personalis in the 2nd quarter worth approximately $35,000.

Source: https://www.americanbankingnews.com/2023/06/23/aaron-tachibana-sells-6904-shares-of-personalis-inc-nasdaqpsnl-stock.html

This isn't just about technology; it's about giving patients and their families a clearer path forward in their fight against cancer," said Chris Hall, President and CEO of Personalis.

Source: https://www.marketscreener.com/quote/stock/PERSONALIS-INC-60037648/news/Analysis-from-TRACERx-Study-Reveals-More-Sensitive-and-Earlier-ctDNA-Detection-in-Lung-Cancer-Patien-45119792/?utm_medium=RSS&utm_content=20231021